Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 27, 2024 2:08pm

81 Views

Post# 36011081

RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

Vertex's US$4.9 Billion acquisition of the early clinical stage - Phase 1b biotech company Alpine Immune Sciences took approximately 5 months - from start to finsih.

Vertex will initiate a Phase 3 study for Alpine's Phase 1b lead product in H2 2024.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects